Mannkind Corp logo

MNKD

Mannkind Corp

$3.88

Earnings Summary

Revenue
$11.99Mn
Net Profits
$-26Mn
Net Profit Margins
-216.79%

Highlights

Revenue:

Mannkind Corp’s revenue fell -31.22% since last year same period to $11.99Mn in the Q1 2022. On a quarterly growth basis, Mannkind Corp has generated -4.18% fall in its revenue since last 3-months.

Net Profits:

Mannkind Corp’s net profit fell -101.29% since last year same period to $-26Mn in the Q1 2022. On a quarterly growth basis, Mannkind Corp has generated 7.35% jump in its net profits since last 3-months.

Net Profit Margins:

Mannkind Corp’s net profit margin fell -192.66% since last year same period to -216.79% in the Q1 2022. On a quarterly growth basis, Mannkind Corp has generated 3.31% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Mannkind Corp post its latest quarter earnings

EPS Estimate Current Quarter
-0.09
EPS Estimate Current Year
-0.09

Highlights

EPS Estimate Current Quarter:

Mannkind Corp’s earning per share (EPS) estimates for the current quarter stand at -0.09 - a 10% jump from last quarter’s estimates.

EPS Estimate Current Year:

Mannkind Corp’s earning per share (EPS) estimates for the current year stand at -0.09.

Key Ratios

Key ratios of the Mannkind Corp post its Q1 2022 earnings

Earning Per Share (EPS)
-0.1
Return on Assets (ROA)
-0.19
Return on Equity (ROE)
0
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Mannkind Corp’s earning per share (EPS) fell -100% since last year same period to -0.1 in the Q1 2022. This indicates that the Mannkind Corp has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Mannkind Corp’s return on assets (ROA) stands at -0.19.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Mannkind Corp’s return on equity (ROE) stands at 0.

Dividend Per Share (DPS):

Mannkind Corp declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.1
-0.1
0%

Company Information

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.

Organisation
Mannkind Corp
Headquarters
Westlake Village, California, United States
Employees
241
Industry
Health Technology
CEO
Michael Castagna